Therapy-related acute myeloid leukaemia (t-AML) and therapy-related myelodysplastic syndrome (t-MDS) are well-recognized complications of cytotoxic chemotherapy and/or radiotherapy 1 . There are several features that distinguish t-AML from de novo AML, including a higher incidence of TP53 mutations 2, 3 , abnormalities of chromosomes 5 or 7, complex cytogenetics and a reduced response to chemotherapy 4 . However, it is not clear how prior exposure to cytotoxic therapy influences leukaemogenesis. In particular, the mechanism by which TP53 mutations are selectively enriched in t-AML/t-MDS is unknown. Here, by sequencing the genomes of 22 patients with t-AML, we show that the total number of somatic single-nucleotide variants and the percentage of chemotherapy-related transversions are similar in t-AML and de novo AML, indicating that previous chemotherapy does not induce genome-wide DNA damage. We identified four cases of t-AML/ t-MDS in which the exact TP53 mutation found at diagnosis was also present at low frequencies (0.003-0.7%) in mobilized blood leukocytes or bone marrow 3-6 years before the development of t-AML/t-MDS, including two cases in which the relevant TP53 mutation was detected before any chemotherapy. Moreover, functional TP53 mutations were identified in small populations of peripheral blood cells of healthy chemotherapy-naive elderly individuals. Finally, in mouse bone marrow chimaeras containing both wild-type and Tp53 1/2 haematopoietic stem/progenitor cells (HSPCs), the Tp53 1/2 HSPCs preferentially expanded after exposure to chemotherapy. These data suggest that cytotoxic therapy does not directly induce TP53 mutations. Rather, they support a model in which rare HSPCs carrying age-related TP53 mutations are resistant to chemotherapy and expand preferentially after treatment. The early acquisition of TP53 mutations in the founding HSPC clone probably contributes to the frequent cytogenetic abnormalities and poor responses to chemotherapy that are typical of patients with t-AML/t-MDS.
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t-AML and t-MDS are clonal haematopoietic disorders that typically develop 1-5 years after exposure to chemotherapy or radiotherapy 1 . To understand better how prior cytotoxic therapy contributes to the high incidence of TP53 mutations and karyotypic abnormalities in t-AML/ t-MDS, we sequenced the genomes of 22 cases of t-AML, including one case that has been previously reported 5 . These data were compared to whole-genome sequence data previously reported for de novo AML 6 and secondary AML (s-AML) arising from MDS for which patients did not receive chemotherapy except hydroxyurea 7, 8 . Of the sequenced t-AML cases, 23% had rearrangements of MLL (also known as KMT2A), 23% had complex cytogenetics, and 36% had normal cytogenetics (Extended Data Table 1 and Supplementary Table 1) .
We predicted that DNA damage induced during exposure to cytotoxic therapy would manifest itself in t-AML genomes with an increased mutation burden. However, the total number of validated somatic singlenucleotide variants (SNVs) and genic (tier 1) somatic SNVs identified was similar to that for de novo AML and s-AML (Fig. 1a, b) . Likewise, the number of small insertions or deletions (indels) in genic regions was similar in t-AML, de novo AML and s-AML (Fig. 1c) . A previous study showed that transversions are specifically enriched in relapsed AML after chemotherapy 9 . However, the percentage of transversions, and in fact of all six classes of SNVs, was similar in all three cohorts (Fig. 1d, e) . Structural variants and somatic copy number alterations were uncommon in these t-AML cases (Supplementary Table 2 and Extended Data Fig. 1a) . Moreover, the number of identifiable subclones in t-AML was similar to that observed in de novo AML (Fig. 1f and Extended Data  Fig. 1b) . Collectively, these data show that the mutation burden of t-AML genomes is similar to that of de novo AML genomes.
We next asked whether the pattern of genes frequently mutated in t-AML/t-MDS is distinct from that observed in de novo AML/MDS. Whole-genome sequencing identified an average of 10.2 6 7.1 missense, nonsense, in-frame indel or frameshift mutations per t-AML genome (Supplementary Table 3 ). To define better the frequency of specific mutations in t-AML/t-MDS, we sequenced a panel of 149 AML/MDS-related genes in an additional 89 patients with t-AML or t-MDS (Supplementary Table 4 ). We combined the whole-genome sequence data with the extension series to report on 52 cases of t-AML and 59 cases of t-MDS. Abnormalities of chromosome 5 or 7 or complex cytogenetics were present in 55.0% of cases (Extended Data Table 2 and Supplementary Table 1 ). The t-AML/t-MDS data were compared to 199 previously reported de novo AML genomes or exomes 6 , or 150 previously reported cases of de novo MDS in which extensive candidate gene sequencing was performed 8 . As reported previously, TP53 mutations are significantly enriched in t-AML/t-MDS compared with de novo AML/MDS (Fig. 1g , h and Supplementary Table 5 ). Interestingly, mutations of ABC transporter genes, a subset of which have been implicated in chemotherapy resistance, are also enriched in t-AML versus de novo AML. On the other hand, several well-defined driver gene mutations (that is, DNMT3A and NPM1) were significantly less common in t-AML. Thus, although the total mutation burden is similar, a distinct subset of mutated genes is present in t-AML/ t-MDS.
TP53 is the most commonly mutated gene in t-AML/t-MDS, with 33.3% of patients affected in our series (Fig. 1g, h) ; the vast majority of these mutations have previously been identified as pathogenic 10 . Multivariate analysis revealed that TP53 mutations were associated with poor risk cytogenetics and a worse prognosis (Supplementary Tables 6, 7 and Extended Data Fig. 2 ), both hallmarks of t-AML/t-MDS. These observations suggest a central role for TP53 mutations in the pathogenesis of many cases of t-AML/t-MDS. However, the mechanism by which TP53 mutations are selectively enriched in t-AML/t-MDS is unclear. The mutation burden in the genomic region containing TP53 (including silent tier 1, and any tier 2 or tier 3 mutations) is similar between t-AML and de novo AML (Extended Data Fig. 1c) . Thus, it is not likely that chemotherapy directly induces TP53 mutations. We recently reported that individual HSPCs accumulate somatic mutations as a function of age, such that by age 50, there are on average five coding gene mutations per HSPC 11 . On the basis of these data and on current estimates that there are approximately 10,000 haematopoietic stem cells (HSCs) in humans 12 , we predict that 44% of healthy individuals at 50 years of age may have at least one HSPC that carries a randomly generated, functional TP53 mutation (see Methods). TP53 has a central role in regulating cellular responses to genotoxic stress [13] [14] [15] [16] [17] , and loss of TP53 provides a selective advantage for neoplastic growth 18 . Together, these observations suggest a model in which rare HSPCs carrying age-related TP53 mutations are resistant to chemotherapy and expand preferentially after treatment (Extended Data Fig. 3) .
This model suggests the following testable predictions: (1) in patients with t-AML containing clonal TP53 mutations, HSPCs harbouring the specific TP53 mutation will be present long before the development of overt t-AML; (2) somatic TP53 mutations will be present in the HSPCs of some healthy individuals never exposed to cytotoxic therapy; and (3) HSPCs harbouring TP53 mutations will expand under the selective pressure of chemotherapy.
To test the first prediction, we identified seven cases of t-AML/t-MDS with specific TP53 mutations for which we had leukapheresis or bone marrow specimens banked 3-8 years before the development of t-AML/ t-MDS (Extended Data Table 3 ). Of note, in all the cases, the TP53 mutation was clonal in the t-AML/t-MDS diagnostic sample. Current nextgeneration sequencing technology is limited in the detection of rare variant alleles owing to an intrinsic sequencing error rate of , 0.1% (ref. 19 ). To overcome this limitation, we introduced random barcodes during production of the sequencing libraries, such that sequence 'read families' containing unique barcodes are generated (Extended Data Fig. 4a ). Using tumour DNA with a known TP53 mutation, we show that this assay can detect a variant allele with a frequency of 0.009% (Extended Data Fig. 4b, c) .
The specific TP53 mutation present in the diagnostic t-AML/t-MDS sample was identified in previously banked specimens in four out of the seven cases tested (see Supplementary Notes for case presentations). In 
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the other three cases, we were unable to detect the diagnostic TP53 mutation in the previously banked blood or bone marrow sample; it is not clear whether these mutations were present but below our limit of detection or were truly absent. Patient 530447 developed t-AML after an autologous stem cell transplant for refractory Hodgkin's lymphoma (Fig. 2a) . The diagnostic t-AML sample carried biallelic mutations of TP53, missense mutations of TET2 and NUP98, a silent mutation of CSMD1, and a subclonal KRAS mutation. Analysis of a leukapheresis sample obtained 6 years before the development of t-AML revealed that both TP53 mutant alleles were present with a variant allele fraction (VAF) of approximately 0.5% (Fig. 2b) . The CSMD1 mutation was also present at the same VAF and is probably a passenger mutation. However, two potential driver mutations (TET2 and NUP98) were not detectable in the previously banked sample. Thus, these data show that, in this patient, the biallelic TP53 mutations preceded the development of t-AML by at least 6 years and antedated the development of the TET2 and NUP98 mutations (Fig. 2c) . In a second case (unique patient number (UPN) 341666), a heterozygous TP53 R196* mutation was identified in mobilized peripheral blood leukocytes 3 years before the development of t-MDS at a frequency of 0.1%, preceding the acquisition of a RUNX1 mutation (Extended Data Fig. 5 ).
In two of the four cases, the previously banked sample was obtained before the initiation of chemotherapy. Patient 967645 developed t-AML 5 years after the diagnosis of marginal zone lymphoma (Fig. 3a) . The diagnostic t-AML sample contained a homozygous TP53 Y220C mutation. Using a droplet digital polymerase chain reaction (ddPCR) assay, we identified the same TP53 Y220C mutation in a bone marrow sample obtained before any chemotherapy at a frequency of 0.0027% (average of two independent experiments) (Fig. 3b) . We next asked whether other mutations in the diagnostic t-AML sample were also present in this previously banked sample (Supplementary Table 8 ). We focused on the G155S mutation in SNAP25; this mutation is probably non-pathogenic as SNAP25 is not expressed in AML samples 6 . Indeed, we identified the SNAP25 G155S mutation in the previously banked bone marrow sample with a similar VAF (0.0029%) as that for TP53 Y220C (Fig. 3c) . Of note, deletion (del)(5q) and del(7q) were subclonal at diagnosis (present in 54% and 38% of metaphases, respectively) (Supplementary Table 1) . Collectively, these data provide evidence that an HSPC harbouring a TP53 Y220C mutation preferentially expanded after chemotherapy with the subsequent acquisition of del(5q) and then del(7q) (Fig. 3d) . Of note, we found two other cases of t-AML/t-MDS with clonal TP53 mutations but subclonal del(5q), del(5) and/or del(7) (UPNs 756582 and 837334, Supplementary Table 1) . Together, these data suggest that TP53 mutations precede the development of these characteristic cytogenetic abnormalities of t-AML/t-MDS.
In a second case, patient 895681 developed t-MDS 5.5 years after the initiation of chemotherapy for non-Hodgkin's lymphoma (Fig. 3e) . The diagnostic t-MDS sample contained a clonal TP53 H179L mutation. Using ddPCR, we identified TP53 H179L at a VAF of 0.05% in a bone marrow sample taken before the initiation of cytotoxic therapy (Fig. 3f) . Thus, as with patient 967645, an HSPC carrying a functional TP53 mutation was present before cytotoxic therapy exposure, later giving rise to the malignant t-AML/t-MDS clone (Fig. 3g) .
To determine whether HSPCs harbouring TP53 mutations are present in healthy individuals, we analysed peripheral blood leukocytes from 20 elderly (68-89 years old) cancer-free donors who had not received prior cytotoxic therapy. We limited our sequencing to exons 4-8 of TP53 since the majority of pathogenic mutations in TP53 are located in these exons. Using our unique adaptor sequencing assay, we identified TP53 mutations in 9 of 19 evaluable cases, with VAFs ranging from 0.01% to 0.37% (Extended Data Table 4 ). Of note, since we did not sequence the entire coding region of TP53, it is likely that our study underestimates the true frequency of healthy elderly individuals harbouring HSPCs with TP53 mutations. ddPCR confirmed the presence of the TP53 mutation in all three cases that were tested (Extended Data Fig. 6 ). Interestingly, the majority of the TP53 mutations identified are known pathogenic mutations previously implicated in cancer. These data suggest that functional TP53 mutations may confer (even in the absence of cytotoxic therapy) a subtle competitive advantage that results in modest HSPC expansion over time.
To test directly the hypothesis that functional TP53 mutations confer a competitive advantage after chemotherapy, we generated mixed bone marrow chimaeras containing both wild-type and Tp53 1/2 cells (Fig. 4a) . In mice treated with vehicle control, we observed a non-significant trend towards an increased Tp53 1/2 donor contribution to haematopoiesis (Fig. 4b-e) . Whether longer follow-up would confirm a subtle competitive advantage, as suggested by the expansion of TP53 mutant HSPC clones in elderly healthy individuals, will require additional study. Regardless, The labelling scheme is the same as in b. g, Proposed model of clonal evolution to t-MDS in case 895681; the diagnostic t-MDS sample contained a subclonal ETV6 mutation.
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upon treatment with N-ethyl-N-nitrosourea (ENU), Tp53 1/2 HSPCs show a competitive advantage. Importantly, a previous study similarly showed that Tp53 1/2 HSCs also have a competitive advantage after irradiation, which appeared to be due, at least in part, to reduced irradiationinduced senescence in . There is increasing evidence that cancers undergo clonal evolution under the selective pressure of chemotherapy 22 . For example, the clonal architecture of de novo AML is dynamic, with certain (often minor) subclones becoming dominant at relapse after chemotherapy 9 . We show that HSPCs that acquire heterozygous TP53 mutations as a function of normal ageing are also subject to Darwinian selection upon exposure to cytotoxic therapy, ultimately resulting in the expansion of HSPCs with these mutations. The high frequency (nearly 50%) of elderly individuals with detectable heterozygous TP53 mutations in their circulating leukocytes far exceeds the prevalence of AML or MDS in this age group. Clearly, additional mutations, including mutation of the second TP53 allele, are needed for transformation to AML or MDS. Consistent with this observation, only a minority of patients with Li-Fraumeni syndrome, most of whom harbour germline heterozygous TP53 mutations, develop AML or MDS 23 . This model provides a potential mechanism for the high incidence of TP53 mutations in t-AML/t-MDS 24 . The TP53 mutation in the founding clone probably contributes to the frequent cytogenetic abnormalities and poor response to chemotherapy that are typical of t-AML/t-MDS. For t-AML/t-MDS cases that do not harbour TP53 mutations, it will be important to determine whether different age-related mutations also confer a competitive advantage to HSPCs that are exposed to cytotoxic therapy, and to define the nature of these mutations.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. 1/2 cells. Data represent the mean 6 standard error of the mean (s.e.m.) of 11 and 14 mice in the ENU and vehicle cohorts, respectively. Peripheral chimaerism was analysed using two-way ANOVA and KLS chimaerism was analysed using an analysis of covariance (ANCOVA).
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METHODS
Patient characteristics. For the whole-genome sequencing study, we intentionally selected the original 22 cases of t-AML to have minimal numbers of cytogenetic abnormalities. However, the additional 89 cases of t-AML/t-MDS were randomly selected from those samples with sufficient tumour and skin DNA. All patients were selected from a larger cohort of adult AML and MDS patients enrolled in a single institution tissue banking protocol that was approved by the Washington University Human Studies Committee (WU HSC#01-1014). Written informed consent for whole-genome sequencing was obtained from all study participants. Patients were treated in accordance with National Comprehensive Cancer Network (NCCN) guidelines (http://www.nccn.org) with an emphasis on enrolment in therapeutic clinical trials whenever possible. Clinical data for all patients, including the preexisting condition requiring cytotoxic therapy, the cytotoxic therapy received before the t-AML/t-MDS diagnosis, cytogenetics, treatment approach and outcomes data, are presented in Extended Data Tables 1 and 2 and Supplementary Table 1 . Peripheral blood leukocyte genomic DNA from cancer-free individuals (median age 5 75.3 6 6.6 years) was obtained as part of a Washington University Institutional Review Board-approved protocol. All subjects had no previous history of invasive cancer or treatment with cytotoxic therapy, as determined by the medical history. Whole-genome sequencing and variant detection. A previously described procedure 25 was followed for library construction and whole-genome sequencing. Briefly, Illumina DNA sequencing was used to generate sequence that covered the haploid reference at a depth between 30.51 and 72.60 (Supplementary Table 9 ). Sequence data were aligned to reference sequence build NCBI human build 36 using BWA v.0. . Somatic copy number alterations were detected using copyCat v.1.5 (http://github.com/chrisamiller/copycat). We detected structural variants using BreakDancer v.1.2 (ref. 31 ) and SquareDancer v.0.1 (https://github.com/genome/genome/ blob/master/lib/perl/Genome/Model/Tools/Sv/SquareDancer.pl), followed by assembly with Tigra-SV (https://github.com/genome/tigra-sv). SciClone (in review; http:// github.com/genome/sciclone) was used to infer the subclonal architecture of all whole-genome sequencing samples. Validation and extension sequencing with variant detection. We used custom sequence capture arrays from Roche Nimblegen that targeted variants detected by whole-genome sequencing and extended this array to cover all coding exons from an additional 149 genes of interest (Supplementary Table 4 ). Libraries were prepared, sequence was generated, and somatic alterations identified as described for whole-genome sequencing with the addition of VarScan v.2.2.6 (ref. 32) (params: -min-var.-freq 0.08-p-value 0.10-somatic-p-value 0.01 -validation) as a variant caller for both SNVs and indels. On average, genes were covered with a depth of 58.3 (Supplementary Table 10 ). Biallelic TP53 mutations in case 530447 were confirmed with PCR amplification of the genomic region containing both somatic mutations from the diagnostic t-AML sample. The resulting amplicons were cloned into the pCR-TOPO plasmid vector (Life Sciences) and sequenced using Sanger sequencing. Statistical analyses. Fisher's exact tests were used to evaluate the association between pairs of dichotomous variables, with a significant right-sided P value indicating a positive relationship and a significant left-sided P value indicating a negative relationship. The relationship between overall survival and each discrete measure was tested with Kaplan-Meier survival analyses with separate analyses for the AML and MDS groups. Age at diagnosis was discretized into quartiles for each group. Multivariate proportional-hazards regression models were created separately for the AML and MDS groups. All variables with log-rank P values of 0.20 or less in the Kaplan-Meier analyses were included in the first step. In successive steps, the variable with the largest P value was removed and the model re-run until all remaining variables had P values of 0.05 or less. Two-way interactions among the remaining variables were examined. Variables removed in earlier steps were added back to the model one at a time to determine if they significantly improved the final model. The proportionality assumption was evaluated for each variable in the final models. Rare variant detection using unique adaptor next-generation sequencing. Amplicons approximately 200 bp in length were prepared from patient genomic DNA samples using primers designed to amplify genomic regions harbouring known tumour-specific SNVs (Supplementary Table 11 ). These amplicons were prepared for next-generation sequencing (NGS) using the Illumina TruSeq DNA Sample Preparation Kit (Illumina Catalog #FC-121-2001) replacing the kit adapters with adapters containing a random nucleotide index sequence. Libraries were quantified using the Agilent qPCR NGS Library Quantification Kit, Illumina GA (Agilent Technologies Catalog #G4880A). Using this quantification, each library was diluted to ensure that each random index would be observed in multiple sequenced reads 33, 34 . Each diluted library was amplified and sequenced on the Illumina MiSeq platform.
Sequenced reads containing the same index sequence were grouped together creating 'read families' in a manner similar to established methods 33, 34 . Reads within a read family were aligned against each other to filter out stochastic sequencing errors generating an error-corrected read family consensus sequence. Each consensus sequence was locally aligned to UCSC hg19/GRCh37 using bowtie2 (ref. 35 ) with the default settings. The aligned read families were processed with Mpileup 27 using the parameters -BQ0 -d 10000000000000. Next, variants were called with VarScan 32 using the parameters -min-coverage 10000-min-reads2 10-min-avg-qual 0-minvar.-freq 0-p-value 1. Variant allele frequencies for the expected mutations and the background error rate were visualized using IGV 36 and graphically represented using ggplot2 (ref. 37) . Variant coordinates are displayed in hg18/GRCh36. Detection of somatic TP53 mutations in cancer-free subjects. Amplicons were prepared from healthy control genomic DNA samples using primers designed to amplify exons 4-8 of TP53 (Supplementary Table 11 ). Patient-specific barcodes, 6 nucleotides in length, were appended to the 59 end of each primer to enable pooling of multiple samples for sequencing. Amplicons generated from each TP53 exon/ patient sample combination were generated as previously described and purified products were pooled in equimolar amounts. The pooled barcoded amplicons were prepared for error-corrected sequencing as previously described. Sequencing was completed on the Illumina Hi-Seq 2500 platform. Sequenced reads were demultiplexed based on the known patient-specific barcode sequences using a 2-nucleotide hamming distance. Demultiplexed sequence reads were organized into read families based on their random oligonucleotide index sequence and error-corrected as outlined previously. Read families composed of three reads or more were used for analysis. A binomial distribution of the substitution rate at each covered base in TP53 was used to identify individuals with somatic TP53 mutations. A variant was called if it met the following criteria: (1) the binomial P value was less than 10
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; (2) the VAF was greater than 1:10,000; (3) at least 10,000 unique read families were sequenced at the position of interest; (4) at least 10 read families called the variant; and (5) the VAF in the individual was greater than five times the mean VAF for all individuals with greater than 10,0003 coverage at that specific nucleotide. Read families from one patient sample (barcode GTACGGC) were removed from analysis due to a high error rate. All somatic mutations were identified in this manner except for TP53 Y220C, which received closer manual inspection due to the large number of these mutations observed in our t-AML cohort. Extraction of genomic DNA from FFPE samples. Genomic DNA was extracted from FFPE samples with the QIAamp DNA FFPE Tissue Kit. Because of the effects of formalin fixation (cross-linking, DNA fragmentation, and so on), the amount of amplifiable DNA per sample was less than would be expected with Qubit fluorometric quantitation. As such, ddPCR was used to quantify the amount of amplifiable genomic DNA per sample such that the numbers of amplifiable domains tested were comparable between experimental and control samples. ddPCR. All primers and probes for ddPCR were designed by Bio-Rad as per MIQE guidelines 38 . In the case of TP53 Y220C, the TP53 region of interest in exon 6 was amplified with the following primers: 59-TTTTCGACATAGTGTGGTG-39 and 59-CTGACAACCACCCTTAAC-39. The 59-Hex/TGCCCTATGAGCCGCCT/Iowa Black FQ-39 probe was used to detect the wild-type allele and the 59-FAM/CCCT GTGAGCCGCCTGA/Iowa Black FQ-39 probe was used to detect the mutant allele. All reagents were purchased from Bio-Rad. ddPCR was performed as previously described 39 . Specifically, quantitative PCR was performed with 900-1,800 nM forward and reverse primers, 250 nM mutant and wild-type genomic probes, and 2-4 ng ml 21 genomic DNA. Quantitative PCR was performed with annealing/extension temperatures of 55.5-60 uC for 40 cycles. For droplet generation and analysis, we used the Bio-Rad QX100 and QX200 Droplet Digital PCR Systems.
Owing to the fact that DNA degradation with time (that is, guanosine oxidation, cytosine deamination) is known to interfere with rare allele detection 34 , we only identified variant alleles present in droplets also lacking the reference allele. This greatly increased the specificity of our calls by removing droplets in which one of the two DNA strands may have been chemically altered. At low variant allele frequency, it was assumed that only a single variant allele was present in these 'mutant only' drops. Droplet allele distribution follows a Poisson distribution such that the number of droplets only containing a single allele (either variant or reference) can be determined from the percentage of empty droplets. Of note, droplets showing evidence of template independent amplification (that is, observed in 'no template controls') were counted as empty droplets. The VAF was determined from the fraction of the single allele droplets containing the variant allele. When appropriate, control samples were used to subtract potential background signal. VAFs calculated in this method were highly concordant with VAFs obtained through uniqueadaptor NGS. Generation and analysis of Tp53 1/2 bone marrow chimaeras. Tp53 1/2 and wildtype mice were inbred on a C57BL/6 strain. Bone marrow from Tp53 1/2 mice expressing Ly5.2 was mixed at a 1:7 ratio with bone marrow from wild-type mice expressing Ly5.1 and transplanted retro-orbitally into lethally irradiated Ly5.1/5.2
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recipients. Tp53 1/2 and wild-type donors were both age (6-12 weeks) and sex matched (female). A total of 3 3 10 6 cells were injected per recipient mice. Recipient mice were conditioned with 1,000-1,100 cGy from a 137 caesium source at a rate of approximately 95 cGy min 21 before transplantation. Prophylactic antibiotics (trimethoprim-sulfamethoxazole; Alpharma) were given during the initial 2 weeks after transplantation. Five weeks after transplantation, mice were given two doses of ENU (100 mg kg
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; Sigma-Aldrich) or vehicle alone intraperitoneally 9 days apart. Mice were stratified according to Tp53 1/2 chimaerism and then randomly distributed into the ENU and vehicle controls such that both cohorts had similar levels of Tp53 1/2 chimaerism at baseline. ENU and placebo were delivered in a final solution with 10% DMSO, 90 mM sodium citrate, and 180 mM sodium phosphate, pH 5.0. Peripheral blood chimaerism was measured before ENU administration and 4-12 weeks after ENU administration. The investigator was not blinded. Mice were euthanized and bone marrow chimaerism analysed 12 weeks after ENU administration. The desired cohort size was determined based on observations from previously reported experiments 20 , and two independent experiments were performed. Mice were maintained under standard pathogen-free conditions according to methods approved by the Washington University animal studies committee. Flow cytometry. Flow cytometry data were collected on a Gallios 10-colour, 3-laser flow cytometer (Beckman Coulter) and analysed with FlowJo software (Treestar). Cells were stained by standard protocols with the following antibodies (eBiosciences unless otherwise noted): Ly5.1 (A20, CD45.1), Ly5.2 (104, CD45.2), Ly6C/G (RB6-8C5, Gr-1), CD3e (145-2C11), CD45R (RA3-6B2, B220), CD11c (N418), TER-119, CD41 (MWReg30), CD117 (ACK2, c-Kit) and Ly-6A/E (D7, Sca). Estimation of TP53 mutation frequency in ageing stem cells. The frequency and profile of somatic single-nucleotide mutations in the HSCs of normal individuals have been previously measured 11 . The somatic mutational burden is ageing-related, and the estimated rate of mutagenesis obtained from this study was 3. 
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) for the average nucleotide in the exome. Thus, we would predict an average 50 year old to have 1.6 3 10 27 mutations per position. These mutations would not be randomly distributed but biased (in particular towards C to T/G to A transitions). It has been previously proposed that an individual possesses approximately 10,000 distinct HSCs 12 . We used a randomized Monte Carlo simulation to model the prevalence of somatic single-nucleotide mutations in healthy 50 year olds with 10,000 HSCs given a normal somatic mutational profile and mutation rate. Repeated simulation (n 5 100,000) allowed us to predict the distribution of ageing-induced TP53 (NM_000546) somatic mutations. As expected, this simulation modelled a Poisson process. We classified TP53 mutations as likely to be functional if they fulfilled both of the following criteria. First, we analysed the mutations using the SIFT program (http://sift.jcvi.org) and required a SIFT score # 0.05. Second, we required that the somatic mutations be reported at least once if a nonsense mutation or at least twice if a missense mutation in the International Agency for Research on Cancer TP53 database (http://p53.iarc.fr). On the basis of this simulation, we predict that 44% of 50-year-old individuals harbour one or more HSCs with a functional TP53 mutation. RESEARCH LETTER
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